Coming to Terms with Painful Challenges
source: pixabay.com

Coming to Terms with Painful Challenges

Life is filled with endless ups and downs. The first 5 of my ongoing 20 years living with dystonia were pretty much nothing but down times. I experienced the most horrible pain…

Continue Reading Coming to Terms with Painful Challenges
INFILTR8: A New and Rare Genetic Disease
source: pixabay.com

INFILTR8: A New and Rare Genetic Disease

  Pursuing an education can be difficult enough without any other extraneous factors. But what if you were also battling frequent infections, gastrointestinal problems, and recurrent hospitalizations? For Evan Brandon,…

Continue Reading INFILTR8: A New and Rare Genetic Disease
Three Poster Presentations Demonstrate The Long-Term Efficacy of Mavorixafor in Primary Immunodeficiencies
source: pixabay.com

Three Poster Presentations Demonstrate The Long-Term Efficacy of Mavorixafor in Primary Immunodeficiencies

X4 Pharmaceuticals Inc. has recently published data from 3 different posters which were presented at the American Society of Hematology (ASH) Annual Meeting in Georgia. You can read the full…

Continue Reading Three Poster Presentations Demonstrate The Long-Term Efficacy of Mavorixafor in Primary Immunodeficiencies

Positive Phase 1 Trial Results for Systemic Sclerosis-Associated Interstitial Lung Disease Treatment

Prometheus Biosciences Inc. has just announced positive results from their Phase 1 investigation for a new treatment for systemic sclerosis-associated interstitial lung disease (SSC-ILD). This trial investigated PRA023, an anti-TL1A…

Continue Reading Positive Phase 1 Trial Results for Systemic Sclerosis-Associated Interstitial Lung Disease Treatment

Phase 1 Trial Produces Positive Results for Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Discerna Pharmaceuticals has just announced the results from a Phase 1 trial investigating their GalXC™ RNAi therapy (Belcesiran) for alpha-1 antitrypsin (AAT) deficiency-associated liver disease (AATLD). The results demonstrated both…

Continue Reading Phase 1 Trial Produces Positive Results for Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Pregnancy Considerations for Women With Interstitial Lung Disease and an Autoimmune Condition

A retrospective medical records study for interstitial lung disease (ILD) has just been published in Arthritis Care & Research. The results found that for women diagnosed with ILD as well as an…

Continue Reading Pregnancy Considerations for Women With Interstitial Lung Disease and an Autoimmune Condition
Biomarker For Acute Aortic Syndrome May be Especially Important To Evaluate in Connective Tissue Disorders
source: pixabay.com

Biomarker For Acute Aortic Syndrome May be Especially Important To Evaluate in Connective Tissue Disorders

A new study has demonstrated that plasma desmosine could be an acute aortic syndrome biomarker. This also means it could be a potential diagnostic tool. The findings from this study…

Continue Reading Biomarker For Acute Aortic Syndrome May be Especially Important To Evaluate in Connective Tissue Disorders
Study of the Week: Whole Plant Cannabis Succeeds in Rare Childhood Epilepsies Where CBD and Others Fail
source: pixabay.com

Study of the Week: Whole Plant Cannabis Succeeds in Rare Childhood Epilepsies Where CBD and Others Fail

Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…

Continue Reading Study of the Week: Whole Plant Cannabis Succeeds in Rare Childhood Epilepsies Where CBD and Others Fail
Xywav for Idiopathic Hypersomnia Earns Orphan Drug Exclusivity
https://pixabay.com/en/baby-girl-sleep-child-toddler-1151351/

Xywav for Idiopathic Hypersomnia Earns Orphan Drug Exclusivity

Orphan Drug designation is typically granted to drugs or biologics intended to treat, prevent, or diagnose rare diseases; in the United States, these are conditions affecting under 200,000 Americans. Drug…

Continue Reading Xywav for Idiopathic Hypersomnia Earns Orphan Drug Exclusivity
Phase 1 Trial for Primary Biliary Cholangitis Therapy Produces Promising Results
source: pixabay.com

Phase 1 Trial for Primary Biliary Cholangitis Therapy Produces Promising Results

Albireo Pharma Inc. has just announced the results from their Phase 1 clinical trial for A3907, an ASBT inhibitor. The study produced positive results, achieving its primary and secondary endpoints. Researchers…

Continue Reading Phase 1 Trial for Primary Biliary Cholangitis Therapy Produces Promising Results